JP2019534285A - 放射エネルギーによる崩壊の標的とされる癌結合性放射線不透過性ペプチド - Google Patents

放射エネルギーによる崩壊の標的とされる癌結合性放射線不透過性ペプチド Download PDF

Info

Publication number
JP2019534285A
JP2019534285A JP2019522653A JP2019522653A JP2019534285A JP 2019534285 A JP2019534285 A JP 2019534285A JP 2019522653 A JP2019522653 A JP 2019522653A JP 2019522653 A JP2019522653 A JP 2019522653A JP 2019534285 A JP2019534285 A JP 2019534285A
Authority
JP
Japan
Prior art keywords
radiopaque
radiant energy
cancer
peptide
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534285A5 (enExample
Inventor
ジェンセン、スティーブン、ディー．
Original Assignee
カオ グループ、インク．
カオ グループ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カオ グループ、インク．, カオ グループ、インク． filed Critical カオ グループ、インク．
Publication of JP2019534285A publication Critical patent/JP2019534285A/ja
Publication of JP2019534285A5 publication Critical patent/JP2019534285A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/40—Arrangements for generating radiation specially adapted for radiation diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/481—Diagnostic techniques involving the use of contrast agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2019522653A 2016-10-26 2017-10-25 放射エネルギーによる崩壊の標的とされる癌結合性放射線不透過性ペプチド Pending JP2019534285A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662412945P 2016-10-26 2016-10-26
US62/412,945 2016-10-26
PCT/US2017/058269 WO2018081256A1 (en) 2016-10-26 2017-10-25 Cancer binding radio-opaque peptides that are targeted for disintegration by radiant energy

Publications (2)

Publication Number Publication Date
JP2019534285A true JP2019534285A (ja) 2019-11-28
JP2019534285A5 JP2019534285A5 (enExample) 2020-10-08

Family

ID=62023998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522653A Pending JP2019534285A (ja) 2016-10-26 2017-10-25 放射エネルギーによる崩壊の標的とされる癌結合性放射線不透過性ペプチド

Country Status (4)

Country Link
US (1) US20190274645A1 (enExample)
JP (1) JP2019534285A (enExample)
CN (1) CN109963875A (enExample)
WO (1) WO2018081256A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521897A (ja) * 2008-04-14 2011-07-28 ザ ジェネラル ホスピタル コーポレイション 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
US20120269721A1 (en) * 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US20160015829A1 (en) * 2010-07-09 2016-01-21 The Usa As Represented By The Secretary, Department Of Health And Human Services Photosensitizing antibody-fluorophore conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US8180436B2 (en) * 2006-04-12 2012-05-15 The Invention Science Fund I, Llc Systems for autofluorescent imaging and target ablation
US20100183504A1 (en) * 2007-06-14 2010-07-22 Fanqing Frank Chen Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521897A (ja) * 2008-04-14 2011-07-28 ザ ジェネラル ホスピタル コーポレイション 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
US20120269721A1 (en) * 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US20160015829A1 (en) * 2010-07-09 2016-01-21 The Usa As Represented By The Secretary, Department Of Health And Human Services Photosensitizing antibody-fluorophore conjugates

Also Published As

Publication number Publication date
US20190274645A1 (en) 2019-09-12
CN109963875A (zh) 2019-07-02
WO2018081256A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
Vergnon et al. Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers
Sieroń et al. Photodynamic therapy (PDT) using topically applied δ‐aminolevulinic acid (ALA) for the treatment of oral leukoplakia
Dougherty Photodynamic therapy—new approaches
Thomas et al. Intraoperative high‐dose rate interstitial irradiation of hepatic metastases from colorectal carcinoma. Results of a phase I–II trial
Prosst et al. Fluorescence-guided minimally invasive parathyroidectomy: clinical experience with a novel intraoperative detection technique for parathyroid glands
JP2015178002A (ja) 手術時イメージングまたはセンチネルリンパ節バイオプシー用の発光ダイ
US20180093104A1 (en) Light irradiation method, light irradiation device, light irradiation system, device system for photodynamic diagnosis or photodynamic therapy, system for specifying tumor site and system for treating tumor
Barr et al. Local eradication of rat colon cancer with photodynamic therapy: correlation of distribution of photosensitiser with biological effects in normal and tumour tissue.
Smith et al. Experimental studies to assess the potential of photodynamic therapy for the treatment of bronchial carcinomas.
Wang et al. Mucosal ablation therapy of Barrett esophagus
Cortese et al. Hematoporphyrin-derivative phototherapy for local treatment of cancer of the tracheobronchial tree
KR102787110B1 (ko) 열 촉진제 조성물 및 사용 방법
Pacifico et al. Nonsurgical management of Barrett's esophagus with high-grade dysplasia
WO2019244977A1 (ja) 腫瘍治療法
JP2019534285A (ja) 放射エネルギーによる崩壊の標的とされる癌結合性放射線不透過性ペプチド
JP2019534286A (ja) 放射エネルギーによる崩壊の標的とされる癌結合性有色ペプチド
Patrice et al. Endoscopic photodynamic therapy with haematoporphyrin derivative in gastroenterology
Saidi et al. Nonthermal ablation of malignant esophageal strictures: photodynamic therapy, endoscopic intratumoral injections, and novel modalities
Banerjee et al. Bronchoscopic photodynamic diagnosis and therapy for lung cancer
Paczuska et al. Effectiveness of CO2 laser in an experimental mammary gland adenocarcinoma model
Palmer Treatment of common cutaneous tumors using the carbon dioxide laser
AKAKURA et al. The combined treatment for carcinoma of the esophagus with the radical resection and the preoperative irradiation
Buchi Endoscopic laser surgery in the colon and rectum
Pritikin et al. Endoscopic laser therapy in gastroenterology
JP2008017899A (ja) 蛍光診断方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220322